无重叠特征系统性硬化症中特异与非特异自身抗体的临床相关性
本研究为横断面研究,纳入263例无重叠综合征的系统性硬化症(SSc)患者,检测广谱自身抗体并分析其与临床受累的相关性。结果显示SSc特异性抗体阳性率88.2%,非特异性抗体如抗Ro52(36.1%)和类风湿因子(18.5%)亦常见,但仅抗RNP与间质性肺病显著相关(P=0.007)。结论提示在此人群中广谱非靶向抗体检测的常规效用有限。
要点
- 无重叠SSc患者中非特异性抗体常见,但临床相关性有限。
- 仅抗RNP与间质性肺病显著相关(P=0.007)。
- 不支持对此类人群常规进行广谱非靶向抗体检测。
核心结论
- 无重叠特征SSc患者中非特异性和IMID相关自身抗体常见但临床相关性有限,质疑广谱非靶向抗体检测的常规效用。
研究设计与样本
- 横断面研究,纳入263例无重叠综合征的连续SSc患者,采用ELISA和线印迹免疫分析检测广谱自身抗体,临床受累采用标准化定义于末次随访评估。
主要发现
- 队列平均年龄42.4岁,病程8.8年,局限型53.6%、弥漫型35%、无皮肤硬化型11.4%。
- SSc特异性抗体阳性率88.2%,主要为抗Scl70(31.5%)、抗着丝点(27%)和抗RNApol-III(8%),多互斥。
- 非特异性抗体常见,包括抗Ro52(36.1%)和类风湿因子(18.5%)。
- 抗dsDNA、抗Sm和抗Jo1经特异性方法确认阴性。
- 唯一显著临床关联为抗RNP与间质性肺病(P=0.007)。
关键数值与推荐
- SSc特异性抗体阳性率88.2%,抗Scl70 31.5%,抗着丝点27%,抗RNApol-III 8%。
- 非特异性抗体:抗Ro52 36.1%,类风湿因子18.5%。
- 抗RNP与间质性肺病相关P=0.007。
临床怎么用
- 在无重叠特征的SSc患者中,广谱非靶向抗体检测的常规效用有限,应聚焦于SSc特异性抗体及抗RNP(与ILD相关)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The diagnosis of systemic sclerosis (SSc) relies on specific autoantibodies, but the clinical value of non-specific and other immune-mediated inflammatory disease (IMID)-associated antibodies in patients without overlap features is unclear. This study determines the frequency and clinical relevance of a broad autoantibody panel in this well-defined SSc cohort. METHODS: This is a cross-sectional study including 263 consecutive SSc patients without overlap syndromes. A panel was tested for anti-Scl70, anti-centromere, anti-RNApol-III, anti-PM-Scl, anti-dsDNA, anti-Sm, anti-Ro52, anti-La, anti-Jo1, anti-cardiolipin, anti-β2GPI, rheumatoid factor (RF), and anti-CCP by ELISA, and anti-fibrillarin, anti-Ku, anti-Th/To, and anti-RNP by line blot immunoassay. Clinical involvement, assessed at the last follow-up using standardized definitions with data from a structured electronic chart database, was correlated with antibody frequencies. RESULTS: The cohort (n = 263) had a mean age of 42.4 years, disease duration of 8.8 years, and included limited (53.6%), diffuse (35%), and sine scleroderma (11.4%) subtypes. SSc-specific autoantibodies were present in 88.2%, primarily anti-Scl70 (31.5%), anti-centromere (27%), and anti-RNApol-III (8%); these were largely mutually exclusive. Non-specific antibodies were also frequent, including anti-Ro52 (36.1%) and RF (18.5%). Key IMID-associated antibodies, such as anti-dsDNA, anti-Sm, and anti-Jo1, were confirmed negative by specific methods. The only significant clinical association was between anti-RNP and interstitial lung disease (P = 0.007). CONCLUSION: Non-specific and IMID-associated autoantibodies are frequent in SSc patients without overlap but show limited clinical correlation. These findings question the routine utility of broad, untargeted antibody testing in this specific population.
引用
- Franco AS, Lopes MC, Medeiros-Ribeiro AC, et al. Clinical relevance of specific and non-specific autoantibodies in systemic sclerosis without overlap features. Semin Arthritis Rheum. 2026. PMID: 41990462. doi:10.1016/j.semarthrit.2026.152976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。